217 Users Online
Sublingual Drugs Market
The Sublingual drugs are the ones administered by sublingual route i.e., keeping under the tongue. The sublingual glands produce saliva to breakdown the drug quicker. Sublingual drugs are used for the management of the pain, anti-allergens, recovery and when other routes of administration fail to provide relief.
The Sublingual Drugs Market is on rise as this route of administration of drugs plays an important role in the efficacy of the drugs pertaining to its quick diffusing ability as compared to the traditional oral method of drug delivery where the drug has to pass through the gastro intestinal tract which degrades the concentration of the dosage due to gastric juices in the stomach, other acids and enzymatic actions.
The allergic reactions related to foods, pollen grains, common cold, etc. happen to be existing to the nearly 1.5 billion of the world population and the sublingual immunotherapy can be applied to capitalize the opportunity. US Food and Drugs Administration approved Abbreviated New Drug Application (ANDA) for Alvogen which will inspire other players to enter the generic sublingual drugs market and increase the investments in the development of this cost effective vertical.
The ease of dosage delivery will be one of the major drivers of the sublingual drugs market. The sublingual drugs can be administered in the form of tablets, strips, drops or even sprays. The prevalence of the geriatric population and some other factors like increasing awareness, access and affordability could be the boosters in the coming period . The Sublingual drugs market is on rise due to the preference and acceptance for a quicker onset by medical practitioners as well as patients ultimately stimulating the manufacturers to enter the lucrative sublingual drugs .
Some conditions like ulcers in the GI tract, dysphasia, mentally retarded patients and preference over injections in case of children will help grow the market. The application of sublingual route to patients suffering from angina can be seen as one of the drivers of growth of the sublingual drugs market. US Court of Appeals for Federal circuit ruled in favor of Dr. Reddy’s Labs to sell a generic version of Suboxone strips sold as Buprenorphine and Naloxone strips which has increased the generic sublingual drugs market. Lupin Pharmaceuticals launched the first product from pipeline into Sublingual drugs market.
The use of sublingual immunotherapy to treat allergies with the non-invasive techniques will be one of the prime movers in the sublingual drugs market as it is not painful.
The Swiss company BioLingus has patented a novel platform to deliver small molecules, peptides and proteins. It has tie-up with WuXi STA for technology and marketing collaboration for expanding into the APAC region for immunotherapy. The drugs depending on the form factor make up for the business models employed for innovation, cost effectiveness and market entry. The licensing of patent rights, collaborations, mergers, exclusive marketing rights, contract research and manufacturing are some of the strategic actions taken by the key players for the competitive edge in the sublingual drugs market.
The sublingual tablets are the most dispensed product form which is heavily invested by entry of the generic versions, availability and higher adoption rate. The films follow the tablets and the novel technologies associated with drops are yet to be commercialized. The hospital pharmacies will lead in the dispensing of the sublingual drugs market. The nutritional supplements segment of the sublingual drugs market is expected to grow at higher pace due to the acceptance and convenience experienced by the patients.
North America leads the market owing to heavy investments in the Sublingual drugs market. Europe follows the North America due to the prevalence of the patients and aging population. APAC region is expected to grow lucratively as an emerging sublingual drugs market. MEA will be growing slowly due to lack of awareness, technology and adoption.
The key participants operating in the global sublingual drugs market are Actavis pharma, Grunenthal, Teva Pharmaceutical, Ethypharm, .